市場調查報告書
商品編碼
1176558
2023-2030 年全球頸椎間盤置換器械市場Global Cervical Total Disc Replacement Device Market - 2023-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
在預測期內 (2022-2029),頸椎間盤置換裝置的市場規模以 20.9% 的複合年增長率增長。
頸椎間盤置換 (CTDR) 設備是一種治療患有退行性椎間盤疾病 (DDD) 的患者的設備。 頸部疼痛是頸椎區域 DDD 發展的主要原因。 頸椎間盤置換術通過手術切除退化的椎間盤並將人造椎間盤植入椎骨來治療 DDD。 該手術是微創手術,術後恢復更快,住院時間更短,再次手術率更低。
頸椎人工椎間盤置換裝置的全球市場受到頸椎病例數量增加、技術進步、老年人口迅速增加、研發活動增加以改善設備質量和醫療費用飆升。據認為,
增加頸椎間盤置換裝置的益處推動市場增長
在預測期內,不斷增長的老年人口和醫療設備的技術進步將推動市場增長。 根據 2020 年發表在 Spine Journal 上的一篇文章,頸椎間盤置換術 (CDR) 是一種用於治療退行性疾病的運動保留手術。 CDR 的基本原理是在減輕疼痛的同時保持頸部活動度,從而降低鄰近節段疾病的風險。 多項體外研究報告稱,使用運動保持植入物可降低相鄰椎間盤的椎間盤壓力。
此外,當前的頸椎間盤置換術 (TDR) 設計使用多種生物材料,包括聚乙烯、不銹鋼、鈦和鈷鉻 (CoCr)。 最重要的是,這些材料被用作允許在椎間盤空間中進行關節連接的支承面。 植入材料的長期生物學效應包括磨損碎片、宿主炎症免疫反應和導致植入失敗的骨質溶解。
市場參與者提供頸椎間盤置換裝置。 人造椎間盤,例如 Medtronic 的 Prestige LP 頸椎椎間盤,放置在兩個相鄰的頸椎之間,以替代患病的頸椎間盤。 這種人造椎間盤旨在保持兩個相鄰頸椎之間的距離。 兩個 Prestige LP 頸椎間盤替換兩個相鄰的需要手術的患病頸椎間盤。
與頸椎間盤置換相關的風險阻礙了市場增長
但是,頸椎間盤插入重要的神經和血管附近。 醫療保健專業人員仔細定位並保護這些神經和血管,但它們可能會在手術過程中受損。 即使是血管上的一個小傷口也會流血甚至死亡。 神經損傷會導致長期喪失運動能力(癱瘓)和感覺。
COVID-19 影響分析
COVID-19 的出現對全球頸椎間盤置換器械市場產生了重大影響。 根據 2022 年 7 月發表在 World Neurosurgery 上的一篇文章,2020 年第二季度擇期手術急劇下降。 在大流行期間接受手術的患者並發症負擔高,合併發病率和死亡率增加。 美國和世界各地的患者和脊柱外科醫生都感受到了停止擇期脊柱手術的影響。
從外科醫生的角度來看,預計積壓的病例估計需要長達 16 個月的時間才能恢復。 在大流行的前兩個月,腰椎擇期手術減少了 90%。 遠程醫療佔脊柱門診預約的三分之二。 鑑於頸椎和腰椎融合手術的數量持續增加,美國取消選擇性脊柱手術的經濟影響也很明顯。 這些手術是美國最昂貴的手術之一。
Cervical Total Disc Replacement Device Market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 20.9% during the forecast period (2022-2029).
Cervical Total Disc Replacement (CTDR) device treats patients suffering from Degenerative Disc Disorders (DDD). Neck pain is the major cause of the development of DDD in the cervical spine region. Cervical disc replacement surgery is performed to treat DDD, where the degenerated disc is withdrawn surgically, and an artificial disc is implanted in the vertebra. This is a Minimal Invasive Surgery and results in quick recovery post-surgery, short hospital stays, and a downward revision surgery rate.
The global cervical total disc replacement device market is driven by increasing cases of cervical DDD, technological advancements, surge in geriatric population, increasing research and development activities to inprove the quality of device and rising healthcare expanditure.
The growing geriatric population and technological advancements in medical devices drive the market in the forecast period. As per the article published in Spine Journal in 2020, cervical disc replacement (CDR) is a motion-preserving surgical procedure for treating degenerative disorders. The rationale of CDR is to maintain cervical mobility while relieving pain, thereby reducing the risk of adjacent segment disease. Multiple in vitro studies have reported reduced intradiscal pressures in the adjacent level discs when using motion-preserving implants.
Furthermore, current cervical total disc replacement (TDR) designs incorporate various biomaterials, including polyethylene, stainless steel, titanium, and cobalt-chrome (CoCr). These materials are most important in their utilization as bearing surfaces, allowing for articular motion at the disc space. Long-term biological effects of implanted materials include wearing debris, host inflammatory immune reactions, and osteolysis resulting in implant failure.
The market players are offering cervical disc replacement devices. For instance, an artificial disc, such as the Prestige LP cervical disc produced by Medtronic, is placed between two adjacent cervical vertebrae to replace a diseased cervical disc. It is designed to maintain the distance between two adjacent cervical vertebrae. Two Prestige LP cervical discs replace two diseased cervical discs that are next to each other and require surgery.
However, the cervical disc is inserted near important nerves and blood vessels. Healthcare professionals carefully find and protect these nerves and blood vessels, but there is a chance of injury to nerves or blood vessels at the time of the surgery. A little cut to a blood vessel can produce hemorrhage or even death. Injury to a nerve can cause long-term loss of movement (paralysis) or feeling.
The appearance of COVID-19 considerably impacted the global cervical total disc replacement device market. As per the article published in World Neurosurgery in July 2022, Elective surgery declined drastically during the second quarter of 2020. Patients undergoing surgery during the pandemic had a higher comorbidity burden, increasing total complication and mortality rates. The ramifications of canceling elective spine surgery were felt by both patients and spine surgeons in the U.S. and worldwide.
From a surgeon's perspective, the projected backlog of cases was estimated to take as long as 16 months to recover. Elective lumbar spine procedures decreased by 90% in the first two months of the pandemic. Telemedicine comprises two-thirds of outpatient spine appointments. The economic effect of canceling elective sp U.S9 ine surgery was also noticeable, given that cervical and lumbar fusion procedural volumes are consistently rising. These procedures rank among some of the most costly surgeries in the United States.
The radiculopathy segment accounts for the largest market share. Cervical total disc replacement is a routinely used treatment for radiculopathy due to degenerative disease of the cervical spine. The procedure originated to avoid complications seen with the traditional anterior cervical discectomy and fusion.
Cervical radiculopathy is a frequently encountered neurologic condition most often caused by encroachment of a cervical nerve root. It typically presents with neck and arm pain and sometimes sensory loss or loss of motor function in the affected nerve root distribution. The most common cause of cervical radiculopathy is degenerative features, including reduced disc height, osteophyte formation, and disc herniation.
Anterior cervical discectomy and fusion, either as individual implant surgical therapy or with further plating, has been the standard criterion for cervical radiculopathy for decades, and more than 100,000 patients receive this treatment in the US annually. Surgical treatment for cervical radiculopathy is growing in most countries and is projected to rise by more than 10% in the next 20 years.
North America dominates the cervical total disc replacement device market and is expected to show a parallel trend over the forecast period. The market is driven in the North American region by the increasing geriatric population, active key players, and product launches.
The key players apply market strategies such as acquisition and product launches to expand the business. For instance, in February 2021, NuVasive acquired Simplify Medical, which develops the Simplify Cervical Artificial Disc for cervical total disc replacement (cTDR), valued at $150m. With the acquisition, NuVasive can address all key parts of the cervical spine by providing inclusive, procedurally integrated solutions across anterior cervical discectomy and fusion (ACDF), posterior cervical fusion (PCF), and cTDR procedures.
Also, in April 2021, NuVasive, Inc. announced that the NuVasive Simplify Cervical Artificial Disc (Simplify Disc) received approval from the U.S. Food and Drug Administration for two-level cervical total disc replacement (cTDR). In a two-level FDA Investigational Device Exemption study, the Simplify Disc demonstrated clinical superiority at 24 months compared to anterior cervical discectomy and fusion (ACDF).
The cervical total disc replacement device market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Zimmer Biomet Holdings, Medtronic Plc, Depuy Synthes, NuVasive Inc, Centinel Spine, Inc., Ranier Technology Limited, Stryker Corporation, AxioMed LLC, Orthofix International, Globus Medical Inc., among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the cervical total disc replacement device market globally.
For instance,
In August 2021, Orthofix Medical launched the M6-C artificial cervical disc compared to anterior cervical discectomy and fusion for the therapy of contiguous two-level symptomatic cervical radiculopathy in the United States.
Zimmer Biomet is a medical device company founded in 1927 to produce aluminum splints. The headquartered is in Warsaw, Indiana. Zimmer Biomet delivers personalized strategy and tailored solutions so you can manage the pain.
Mobi-C Cervical Disc: The Mobi-C Cervical Disc is developed for cervical disc replacement to repair segmental motion and disc height. The components of Mobi-C include superior and inferior cobalt chromium molybdenum alloy endplates coated with plasma-sprayed titanium and hydroxyapatite coating and a polyethylene mobile bearing insert.
The global cervical total disc replacement device market report would provide access to approximately 60+ market data tables, 60+ figures, and in the range of 200+ (approximate) pages.
LIST NOT EXHAUSTIVE